Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (192${count})

  • Research Grant, 2021
    Comparing the Effectiveness of Two Imaging Methods for Monitoring the Progression of Parkinson’s Disease

    Study Rationale:
    Parkinson’s disease robs the brain of dopamine, a neurochemical needed for normal movement and cognition. A variety of imaging methods can be used to monitor the brain’s dopamine...

  • MJFF Research Grant, 2011
    Multimodal MRI Markers for Parkinson's Disease

    Objective/Rationale: 
    A measurement tool which accurately reflects not only motor deficits but also a host of cognitive dysfunctions seen frequently in Parkinson’s disease (PD) would improve diagnosis...

  • Access to Data and Biospecimens, 2015
    BioFIND: Analysis of A-beta, Tau and P-tau in CSF Samples

    Study Rationale: Mixed pathology is common in all neurodegenerative diseases including Parkinson’s disease (PD).  Three cerebrospinal fluid (CSF) biomarkers, Ab1-42, t-tau and p-tau181, provide an...

  • Therapeutic Pipeline Program, 2014
    Evaluating the Safety, Tolerability and Efficacy of SYN120 in Parkinson’s Disease Dementia

    Study Rationale:
    Cognitive impairments — common in Parkinson’s disease — are associated with an imbalance in neurotransmitters (substances that allow nerve cells to communicate with one another) such...

  • GBA Biology and Therapies, 2018
    Molecular Imaging and Computer Typing in GBA-PD and Asymptomatic GBA-mutation Carriers

    Study Rationale:
    People who have a mutation in the GBA gene have a higher risk of developing Parkinson’s disease (PD) and, if they have PD, are more likely to have cognitive decline and dementia...

  • Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023
    SUPPLEMENT | CMA as a Means to Counteract Alpha-synuclein Pathology in Non-human Primates”

    Study Rationale: One of the main pathways to remove excess amounts of the alpha-synuclein protein that is linked to Parkinson’s disease (PD) is the lysosomal chaperone-mediated autophagy (CMA) pathway...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.